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1036Background: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device
that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously re-
ported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up).
This report summarizes results of extended followup to 5 years.
Methods: A total of 107 patients were enrolled in the no–mitral valve repair/replacement stratum including 57
in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were as-
sessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures,
New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core
laboratory.
Results:Overall survivals were similar between the treatment and control groups, demonstrating no late adverse
effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume
(P ¼ .029) as well as a small increase in sphericity index. More patients in the treatment group improved by
at least 1 NYHA functional class (P¼ .0005). There was no difference in rates of adverse events. In a subgroup
of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the
Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures
(P ¼ .04).
Conclusions: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the
long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with
heart failure who remain symptomatic despite optimal medical therapy. (J Thorac Cardiovasc Surg 2012;143:
1036-42)Earn CME credits at
http://cme.ctsnetjournals.org
Left ventricular (LV) remodeling is the pathophysiologic
hallmark of heart failure (HF). It is characterized by ventric-
ular dilation, a change from an ellipsoidal to a more spherical
chamber shape, cardiomyocyte hypertrophy, interstitial fi-
brosis, and numerous alterations in biochemical and molec-
ular functions.1 LV remodeling is a strong predictor of
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The Journal of Thoracic and Cardiovascular Surclinical outcomes have a beneficial effect on remodeling,
whereas therapies with a known deleterious effect on out-
comes have adverse, neutral, or unknown effects on
remodeling.2
Effective pharmacologic therapies inHFhave operated ei-
ther through a receptor-based mechanism (eg, angiotensin-
converting enzyme inhibitors and beta-blockers) or through
resynchronization (eg, biventricular pacemakers). To date,
no therapy has specifically addressed the remodeling process
or the important contributions of wall stress. The CorCap
cardiac support device (CSD; Acorn Cardiovascular, Inc,
St Paul,Minn) is a polyestermesh device that is fitted around
the ventricles to provide circumferential diastolic support. In
3 different animalmodels of HF, implantation of the CSD re-
sulted in favorable changes in LV size and function consis-
tent with reverse remodeling.3-5 We6 have previously
reported the results of a randomized trial that enrolled 300
patients into 1 of 2 strata including themitral valve repair/re-
placement (MVR) stratum, for patients undergoing MVR
surgery, and the no-MVR stratum for patients who were
solely provided optimal medical therapy. In that report, pa-
tients were followed up to a common closing date, which
was a median of 22.9 months of follow-up. We now report
results of follow-up extending to 5 years, including annual
echocardiograms read by a central core laboratory. Thegery c May 2012
Abbreviations and Acronyms
CSD ¼ cardiac support device
HF ¼ heart failure
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
MVR ¼ mitral valve repair/replacement
NYHA ¼ New York Heart Association
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Dinclusion of 2 different strata made it difficult to interpret the
original report. Although both strata evaluated the impact of
the CorCap device, the control group in the MVR strata also
underwentmitral valve repair or replacement surgery, so that
the incremental impact or benefit of the CorCap CSDwas on
top of the benefit associated with MVR surgery. In the no-
MVR stratum, the impact of the CSD was compared with
medical therapy alone and therefore was the purer test of
the CorCap hypothesis. This report will focus exclusively
on the no-MVR stratum, in which patients were randomized
to CorCap CSD implantation or optimal medical therapy
alone.
METHODS
The Acorn Trial was a prospective and randomized study that enrolled
300 patients into 1 of 2 different strata. Patients with HF who had mitral
regurgitation and a clinical indication for mitral valve surgery were en-
rolled into the MVR stratum (n ¼ 193). Results of this stratum and
5-year follow-up have been presented elsewhere and are not discussed in
this report.7,8 Patients with HF who did not have significant mitral
regurgitation (2þ) were enrolled into the no-MVR stratum. Patients
were randomized to treatment (CorCap CSD plus optimal medical therapy)
or control (optimal medical therapy alone).
Patient Population
Patients enrolled into the no-MVR stratum had New York Heart Asso-
ciation (NYHA) class III-IV HF of either ischemic or nonischemic etiol-
ogy. Patients were between the ages of 18 and 80 years, with an LV
ejection fraction of 35% or less, LV end-diastolic dimension of 60 mm
or more (or an LV end-diastolic dimension indexed to body surface
area 30 mm/m2), 6-minute walk test distance of less than 450 m, and
acceptable laboratory and pulmonary function tests. All patients were
on a stable and optimal medication regimen that included an
angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker
if angiotensin-converting tension–intolerant) and beta-blockers (for at
least 3 months) before randomization. Doses were titrated to recommen-
ded or highest tolerated levels and were kept stable for more than 1
month.
Exclusion criteria have been described previously.6 In particular, pa-
tients were excluded if they had any planned cardiac surgery, existing pat-
ent coronary artery bypass graft, a current or anticipated need for an LV
assist device (LVAD), were on an active cardiac transplant list, had an an-
ticipated need for heart transplantation within the next 2 years, had received
biventricular pacing within the past 3 months, or had anticipated implanta-
tion of such a device within 12 months of enrollment. The protocol and in-
formed consent form were reviewed and approved by the institutional
review board before participation at each of the 29 clinical sites. Before
baseline testing, all patients signed the informed consent form, which al-
lowed follow-up through 5 years.The Journal of Thoracic and CarEnrollment, Baseline Surgery, and Follow-up
Baseline testing included chest radiograph, transthoracic echocardio-
gram, electrocardiogram, 6-minute walk test, maximal cardiopulmonary
exercise test, quality of life tests, and assessment of NYHA class made
by the site physician and by a blinded core laboratory.
After baseline testing, patients were randomized to either treatment or
control. The control group did not undergo any surgery and were main-
tained on optimal medical therapy during follow-up. Crossover from con-
trol to treatment was not permitted. Patients in the treatment group
underwent surgical implantation of the CorCap CSD using a standard ster-
notomy approach, as described previously.9
Follow-up was divided into 2 distinct phases. The pivotal efficacy phase
started with the enrollment of the first patient and ended on a common clos-
ing date, which was defined as the date when the last enrolled patient had
completed 12 months of follow-up. The last patient completed 12 months
of follow-up on July 4, 2004, resulting in a median duration of follow-up of
22.9 months. During the pivotal efficacy phase, patients were seen for clin-
ical assessment and repeat testing at 3 months, 6 months, and then every 6
months until the common closing date. The primary analysis of safety and
efficacy of the CorCap device was based on data from the pivotal efficacy
phase.6
After completion of the primary efficacy phase, patients entered an ex-
tended follow-up phase, in which long-term safety was monitored every
year until 5 years after enrollment. Patient assessments during the extended
follow-up phase included survival, adverse events, major cardiac proce-
dures, and echocardiograms. Patients did not undergo follow-up echocar-
diograms after LVAD implantation or cardiac transplant. At each visit,
patients were seen and evaluated by the principal investigator and research
staff at each site.
All study echocardiograms were sent to the Echocardiography Core
Laboratory at the Mayo Clinic. Each echocardiogram was evaluated by
an extensive protocol specifically looking for evidence of constrictive
physiology based on respiratory variations in mitral flow velocity, hepatic
vein flow reversal, and superior vena cava forward flow velocity, based on
the following definitions:
Definite constrictive physiology. Criteria 1, 2, and 3 are
satisfied.
1. A 25% or greater change in mitral E velocity with respiration, using the
formula:% change ¼ (E exp – E insp)/E insp
2. A 40% or greater increase in diastolic hepatic vein flow reversal veloc-
ity with expiration compared with inspiratory diastolic flow reversal
3. Less than 20 cm/s difference between systolic superior vena caval for-
ward flow velocity with inspiration versus expiration.
Probable constrictive physiology. Criteria 2 and 3 are satisfied,
or criterion 1 or 2 is satisfied with additional 2-dimensional features of
constriction.
No constrictive physiology. There is no evidence of definite or
possible constrictive physiology, as described above.
Further, in cases of adverse events such as hemodynamic compromise
where constrictive physiology was considered a possibility, investigators
were instructed to consider additional testing, including transesophageal
echocardiography, computed tomography, magnetic resonance imaging,
and cardiac catheterization with simultaneous right ventricular and LV
pressure recordings.
Cumulative survival curves for the risk of death, adverse events, andma-
jor cardiac procedures were constructed according to the Kaplan-Meier
method and significance assessed by the log– rank statistic. Comparisons
of change from baseline for echocardiographic parameters were evaluated
with longitudinal regression analysis, using amixed-effects model in which
follow-up visit was the repeated measure and the baseline value was the
covariate.
Data were collected and stored in a database managed by Acorn Cardio-
vascular, Inc. All authors had full access to the data.diovascular Surgery c Volume 143, Number 5 1037
TABLE 1. Baseline characteristics: no-MVR stratum
All patients
(n ¼ 107)
Patients who completed
5-year follow-up (n ¼ 50)
Treatment
(n ¼ 29)
Control
(n ¼ 21) P value (T vs C)
Age (y) 50.8 49.6 49.5 49.8 NS
Gender (%)
Male 72.9 70.0 65.5 76.2 .05
Female 27.1 30.0 34.5 23.8
Race (%)
White (%) 73.8 78.0 79.3 76.2 NS
Black (%) 20.6 18.0 17.2 19.1
Other (%) 5.6 4.0 3.5 4.8
Etiology
Ischemic (%) 16.8 16.0
Idiopathic (%) 62.6 62.0
Alcoholic (%) 2.8 4.0
Hypertensive (%) 9.4 12.0
Viral (%) 12.2 8.0
Valvular (%) 0.9 2.0
Other (%) 7.5 4.0
Medical treatment
ACE I or ARB (%) 96.3 98.0
Beta-blocker (%) 94.4 96.0
NYHA class III 99.1 98.0 96.6 100 NS
LVEF (%) 26.1 27.0 25.3 29.5 .053
LVEDD (mm) 72.6 71.4 72.6 70.0 NS
LVEDV (mL) 282.0 270.7 279.4 264.3 NS
6MWT (m) 334.7 338.9 322.8 361.1 .065
MLHF (units) 62.0 61.5 67.0 54.0 .022
Peak VO2 (mL $ kg
1 $ min1) 16.1 16.1 14.7 18.1 .001
MVR,Mitral valve repair/replacement; T, treatment; C, control; NS, not significant; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NYHA, New York
Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVEDV, left ventricular end-diastolic volume; 6MWT, 6-minute walk
test; MLHF, Minnesota Living with Heart Failure; VO2, Volume of oxygen utilization.
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DRESULTS
Table 1 summarizes the baseline characteristics of pa-
tients in the no-MVR stratum. The first column summa-
rizes the 107 patients originally enrolled.6 The second
column summarizes the baseline characteristics of the 50
patients who completed all 5 years of follow-up. In gen-
eral, the patients completing 5 years of follow-up were
similar to the patients who were originally enrolled with
a mean age of 49.6 years. Most patients were male
(70.0%), had an idiopathic etiology (62%), and were in
NYHA class III (98%). The mean ejection fraction was
27%, the mean 6-minute walk distance was 338.9 m, the
mean Minnesota Living with Heart Failure score was
61.5 units, and the mean peak volume of oxygen utilization
was 16.1 mL $ kg1 $ min1. Among the 50 patients who
completed 5 years of follow-up, the treatment (n ¼ 29)
and control (n¼ 21) groups were reasonably well matched.
However, the control patients tended to be ‘‘less sick’’ on
entry into the trial with a higher LV ejection fraction
(29.5% vs 25.3%; P ¼ .053), lower Minnesota Living
with Heart Failure score (54.0 vs 67.0 units; P ¼ .022),
and higher peak volume of oxygen utilization (18.1 vs
14.7 mL $ kg1 $ min1; P ¼ .001).1038 The Journal of Thoracic and Cardiovascular SurOf the original 107 patients enrolled in the no-MVR stra-
tum, a total of 57 patients did not complete 5 years of
follow-up owing to death (n ¼ 40), lost to follow-up
(n ¼ 10), and withdrawn from study owing to patient/phy-
sician request (n ¼ 7). The median duration of follow-up
was 54.0 months, with 57.4 months in the treatment group
and 51.3 months in the control group. The total follow-up
was 384.9 patient-years.
Figure 1 summarizes 5-year mortality rates. Over the 5
years of follow-up, there were 40 total deaths, including
19 deaths in the control group (overall mortality rate of
38%) and 21 deaths in the treatment group (overall mortal-
ity rate of 36.8%) The mortality curves between the treat-
ment and control groups were very similar, demonstrating
a lack of any late adverse effect on mortality. Causes of
death were reported by the investigators to be primarily car-
diovascular as described in Table 2. There were no signifi-
cant differences in the causes of death between the 2
groups. Neither this follow-up analysis nor the original
Acorn Trial6 was powered to detect a mortality benefit of
the CorCap CSD.
Figure 2 summarizes the longitudinal regression analysis
for the changes in LV end-diastolic volume. The controlgery c May 2012
FIGURE 1. Kaplan-Meier mortality curve for the no-MVR stratum over 5 years of follow-up. Patients in the treatment group (T) are in the solid line and
patients in the control group (C) are in the dotted line. The mortality curves between the treatment and control groups were similar, demonstrating the lack of
any late adverse effect on mortality. CSD, Cardiac support device.
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size over 5 years of follow-up. In contrast, the CSD treat-
ment group showed a progressive decrease in LV end-
diastolic volume that was persistent over 5 years of
follow-up. The differences between the treatment and con-
trol groups appeared to widen in the latter stages of follow-
up. When averaged over 5 years, the treatment group LV
end-diastolic volume was smaller by 28.9 mL compared
with the control group (P ¼ .029). This represents an aver-
age decrease of 10.6% compared with the control group.
For the treatment group, the average decrease in LV end-
diastolic volume compared with baseline was 37.7%. A
similar pattern was observed for LV end-systolic volume
(treatment group smaller than control group by 21.9 mL;
P¼ .096). Since the changes in LVend-diastolic dimension
and LV end-systolic dimension were similar, there were no
significant differences in ejection fraction (estimated treat-
ment difference 0.06 units; P ¼ not significant).
Figure 3 shows the changes in LV sphericity index (ratio
of end-diastolic length/width). The control group had a smallTABLE 2. Causes of death
Causes of death
Treatment group
(n ¼ 57)
Control group
(n ¼ 50)
No. Percent No. Percent
Cardiovascular 14 66 12 63.2
Noncardiovascular 3 14.3 2 10.5
Unknown 1 4.7 3 15.8
Other/miscellaneous 3 14.3 2 10.5
Total 21 19
The Journal of Thoracic and Carincrease in sphericity index over 5 years of follow-up. The
treatment group had a much larger increase in sphericity in-
dex and the difference compared with the control group ap-
peared to increase over time, indicating return to a more
physiologic ellipsoidal shape. The average difference be-
tween the treatment and control groups was 0.038 units,
which was not statistically significant (P ¼ .26).
Table 3 summarizes the number of patients who had se-
rious adverse events through 5 years of follow-up. ThereFIGURE 2. Longitudinal regression analysis for changes in left ventricu-
lar (LV) end-diastolic volume in the no-MVR stratum. The control group
did not demonstrate any consistent changes in LV end-diastolic volume
over 5 years. In contrast, the CSD treatment group showed a progressive
decrease in LV end-diastolic volume that was persistent over 5 years.
When averaged over 5 years, the LVend-diastolic volume of the treatment
group was smaller by 28.9 mL than that of the control group (P ¼ .029).
diovascular Surgery c Volume 143, Number 5 1039
FIGURE 3. Longitudinal regression analysis for changes in left ventricu-
lar sphericity index in the no-MVR stratum. The treatment group had
a much larger increase in sphericity index, indicating a change to a more
ellipsoidal shape. The average 5-year treatment–control difference was
0.038 units, which was not statistically significant.
FIGURE 4. Longitudinal regression analysis for the percentage of pa-
tients with an improvement in New York Heart Association (NYHA) func-
tional class of 1 class or more over 5 years of follow-up in the no-MVR
stratum. At each time point, thereweremore patients in the treatment group
who improved by at least 1 NYHA functional class. When averaged over 5
years, this difference was highly significant. Trt, Treatment; Ct, control.
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control group, compared with 82.5% in the treatment group
(P ¼ .79). The number of patients and the type of adverse
events were not statistically different between the treatment
and control groups.
The most commonly cited concern about CorCap CSD
implantation is the late development of pericardial constric-
tion. However, during the 5-year follow-up, no cases of
pericardial constriction have been detected through adverse
event reporting (hemodynamic compromise). Furthermore,
we used annual surveillance echocardiograms that were
read using a standardized evaluation protocol at the Mayo
Core Laboratory. This protocol was very sensitive to detect
possible changes in diastolic filling.TABLE 3. Adverse events: no-MVR stratum—5-year follow-up
Treatment
(n ¼ 57)
Control
(n ¼ 50) P
valueNo. Percent No. Percent
Allergic response 0 0.0 0 0.0 N/A
Arrhythmia 19 33.3 18 36.0 .84
Bleeding 5 8.8 4 8.0 1.00
Hemodynamic Compromise 39 68.4 30 60.0 .42
Hepatic compromise 0 0.0 0 0.0 N/A
Infection/pneumonia 17 29.8 13 26.0 .67
Myocardial infarction 1 1.8 1 2.0 1.00
Neurologic deficit/stroke 3 5.3 5 10.0 0.47
Peripheral thrombus/
embolism
2 3.5 1 2.0 1.00
Pulmonary compromise 11 19.3 6 12.0 .43
Pulmonary embolism 2 3.5 1 2.0 1.00
Renal compromise 9 15.8 3 6.0 .13
Other 31 54.4 23 46.0 .44
Any of the above SAEs 47 82.5 43 86.0 .79
MVR, Mitral valve repair/replacement; N/A, not available; SAEs, serious adverse
events.
1040 The Journal of Thoracic and Cardiovascular SurIn the entire no-MVR cohort (107 patients), 20 patients at
some point during follow-up (3-60 months) were deemed to
have at least 1 ‘‘probable’’ or ‘‘definite’’ indication of con-
striction based on the echocardiographic measures. Of these
20 patients, 14 were in the treatment group and 6 were in the
control group.
Thirteen patients had only 1 echo diagnosis of ‘‘probable’’
or ‘‘definite’’ constriction throughout the duration of follow-
up (approximately 18% of completed visits), demonstrating
that themajority of positive echo signals of constrictionwere
isolated. In addition, these incidences were not supported by
other clinical evidence, such as corresponding serious ad-
verse event reports of hemodynamic compromise. Seven pa-
tients had multiple visits in which ‘‘probable’’ or ‘‘definite’’
evidence of constriction based on echowas noted. However,
the evidence was not consistent through all follow-up visits
and there were no corresponding clinical indications of he-
modynamic compromise. Of these 7 patients, 4 were in the
control group and 3 were in the treatment group.
NYHA functional class was assessed by site investigators
at each of the follow-up visits. Figure 4 summarizes the per-
cent of patients who improved by 1 NYHA functional class
or more compared with their baseline status. Through 5
years of follow-up, 50% to 60% of patients in the control
group improved by 1 functional class. This observation
likely represents a ‘‘survivor’’ phenomenon, inasmuch as
control patients with advanced HF who are able to survive
5 years are likely to be ‘‘responders.’’ However, at each
time point over 5 years of follow-up, there were more pa-
tients in the treatment group that improved by at least 1
NYHA functional class. When averaged over 5 years, this
difference was highly significant (P ¼ .005).
Subgroup analysis was performed to determine whether
etiology had any effect on the response to the CorCapgery c May 2012
FIGURE5. Kaplan-Meier estimate for the composite of death andmajor cardiac procedure for the focused cohort of the no-MVR stratum. Therewas a large
separation between the groups that was maintained through 5 years of follow-up. The treatment group had fewer deaths, heart transplants, left ventricular
assist devices, and biventricular pacemakers. CSD, Cardiac support device; T, treatment; C, control.
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tients with or without ischemic heart disease. However, only
16% of patients had ischemic heart disease, which may be
too small to detect any differences in the response.
We6 previously reported on a post hoc analysis that iden-
tified a focused cohort as the group of patients who had the
biggest treatment response (patients with an intermediate
LV end-diastolic dimension indexed to body surface area
that was 30 mm/m2 and 40 mm/m2). In the focused co-
hort, overall survival slightly favored the treatment group,
but the difference was not statistically significant
(P ¼ .73). Figure 5 shows the Kaplan-Meier estimate of
the composite of death or major cardiac procedure for the
focused cohort population (n ¼ 56). There was a large sep-
aration between the groups that was maintained during the
entire follow-up period (P ¼ .028). The entire patient pop-
ulation had a similar reduction in this composite end point,
but the difference was not statistically significant (P¼ .15).
The treatment group had fewer heart transplants (4 vs 8),
fewer LVADs (2 vs 4), and fewer biventricular pacemakers
(12 vs 15) than did the control group. There had been con-
cerns about the ability to perform these additional proce-
dures in patients who had received the CorCap device.
However, all the transplants, LVADs, and biventricular
pacemakers were successfully implanted.
DISCUSSION
The principal findings from the 5-year follow-up of the
no-MVR stratum is that the CorCap CSD is safe and asso-
ciated with sustained beneficial effects on LV remodelingThe Journal of Thoracic and Caras well as sustained clinical benefits. The 5-year survival
curves between the treatment and control groups were sim-
ilar, confirming the absence of any late adverse effect on
mortality. In addition, there was no difference in adverse
events. Importantly, there were no signs of pericardial con-
striction, which is the most commonly cited concern of the
CSD. Follow-up echocardiograms analyzed by a core labo-
ratory over 5 years demonstrated persistence of benefit on
LV remodeling with decreases in LV end-diastolic and
end-systolic volumes and improvements in sphericity in-
dex. A greater percentage of patients improved by at least
1 NYHA functional class in the CSD treatment group. Fi-
nally, in a post hoc subgroup analysis of responders (fo-
cused cohort), there was a significant reduction in the
combined end point of death and major cardiac procedures.
Taken together, these 5-year follow-up data confirm the ini-
tial findings from the pivotal efficacy phase of the trial and
suggest that the benefits persist over 5 years.
Previous reports of the Acorn Trial6,10 reported an
analysis that combined both the MVR and the no-MVR
strata. There were some difficulties in interpreting the
data because the control group in the MVR stratum under-
went mitral valve repair, whereas the control group in the
no-MVR stratum were just maintained on optimal medical
therapy. This report focuses exclusively on the no-MVR
stratum, which was the purer test of the CorCap hypothesis
since it compared the results of CorCap CSD versus medi-
cal therapy alone.
Collecting 5-year follow-up data on patients with HF is
difficult. These patients are typically very ill, and manydiovascular Surgery c Volume 143, Number 5 1041
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other clinical trials, or may die. However, these extended
follow-up data are very important for the overall risk–
benefit analysis of CorCap CSD implantation. The original
report of the no-MVR stratum demonstrated a significant
improvement in the primary composite end point
(P ¼ .032), in which patients were considered improved,
the same, or worsened on the basis of survival, the need
for additional major cardiac procedures, and NYHA class.
Advisory panels to the Food and Drug Administration re-
viewed all of the clinical trial data in June 2005 and Decem-
ber 2006. The panels supported the efficacy of the device
but raised concerns about safety owing to the rate of perio-
perativemortality (4/51 patients; 7.8%). Further, there were
concerns about the durability of the benefit and the potential
appearance of constriction during later follow-up. The cur-
rent data set is therefore a very important demonstration that
the benefit is indeed durable and that there is not an in-
creased incidence of late adverse events.
Data on the long-term effects of the CorCap CSD can be
contrasted to the effects of cardiac resynchronization ther-
apy. These specialized pacemakers are often associated
with a dramatic and immediate improvement in symptoms
and reverse remodeling of the left ventricle. However, re-
ports have suggested that this initial benefit is not main-
tained in all patients long-term.11 In contrast, implantation
of the CorCap CSD does not result in immediate clinical
or echocardiographic benefit. However, the beneficial ef-
fects on LV size and shape are maintained for 5 years. To
our knowledge, there are few reports of device therapy
with documented beneficial effects on LV remodeling out
of 5 years of follow-up. Another strength of the current
study is that echocardiograms were read by a central core
laboratory and the readers were blinded to treatment status.
A second-generation CSD was recently developed that
can be implanted through a small thoracotomy incision.
This alternate implant procedure should reduce many of
themorbidities and complications associatedwith a full ster-
notomy. The feasibility and safety of this approach have
been demonstrated in a study of 14 patients with the same
baseline LV dimensions as the focused cohort (intermediate
indexedLVend-diastolic diameter>30 and<40mm/m2). A
confirmatory trial on the safety and efficacy of the CorCap
CSD using this thoracotomy delivery is pending.
This current study is limited by the small number of pa-
tients who completed 5 years of follow-up and by the fact
that other important measures of patient functional class,1042 The Journal of Thoracic and Cardiovascular Sursuch as quality of life and exercise tests, were not completed
during the extended follow-up phase. However, patient
functional class can be affected by noncardiac factors and
comorbidities that may not be improved by the CSD. Fur-
ther, all the clinical assessments were not blinded and are
therefore influenced by physician and patient bias. Finally,
these results could be influenced by surgeon reluctance to
reoperate after CorCap CSD implantation.
In summary, data from 5-year follow-up of the no-MVR
stratum of the Acorn Trial show that implantation of the
CorCap CSD is safe with no apparent long-term complica-
tions or adverse effects on mortality. CSD therapy is associ-
ated with long-term sustained benefits on ventricular reverse
remodeling, a sustained reduction in the combined end point
of death/major cardiac procedures, and a sustained improve-
ment in NYHA functional class. These cumulative data sug-
gest that the CorCap CSD may represent a novel adjunctive
therapy for stabilizing the progression of HF in patients who
remain symptomatic despite optimal medical therapy.References
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